Provide essential “nutrition solution” for biomedicine research and development
It is learned that Opmai Bio has completed a new round of financing of 100 million yuan. Hao Yue Capital serves as the exclusive financial adviser for this round of financing. This round of financing funds will be used to expand the cultivation medium production line and CDMO service platform, and introduce talents and expand overseas business. Prior to this, Opmai Biosciences obtained strategic investment of nearly RMB 100 million from Dachen Venture Capital and Huaxing Medical Industry Fund.
Opmai was established in 2013 and is located in Shanghai International Medical Park. It is positioned as a serum-free medium + CDMO one-stop service platform to achieve domestic substitution of serum-free medium. At present, we mainly provide CDMO services such as cell line construction, process development and pilot test for customers.
During the process of biomedicine research and development, as an indispensable “nutrient solution” for cell culture, current biomedicines such as antibodies, cell therapy, and gene therapy all rely on cell culture. No Serum culture can be said to be a key raw material for biopharmaceutical production, and it is of great significance .
Dr. Zhihua Xiao, founder, chairman and general manager of Opmai, said that in the past two years, with the introduction of a number of blockbuster biopharmaceuticals (PD-1 mAb, rituximab biosimilars, adalim Monoclonal biosimilars, bevacizumab biosimilars, etc.) have been launched in the country, The era of industrialization of domestic antibody drugs is coming ; At the same time, the 4 + 7 centralized procurement and overall price-for-medicine policy of the Medical Insurance Bureau made antibody drugs, especially the highly competitive varieties of drugs, facing severe price pressures, and urgently sought raw materials that could reduce the cost of antibody drug production. As an important raw material (accounting for more than 30% of the cost of biopharmaceutical production), domestic substitution is the general trend. Based on this, he believes that the tens of billions of markets for serum-free medium in the future can be expected.
